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Abstract
Background: In patients treated by maintenance hemodialysis the relationship to survival of
hemoglobin level and administered epoetin-alfa and intravenous iron is controversial. The study aim
was to determine effects on patient survival of administered epoetin-alfa and intravenous iron, and
of hemoglobin and variables related to iron status.
Methods: The patients were 1774 treated by maintenance hemodialysis in 3 dialysis units in New
York, NY from January 1998 to June, 2007. A patient-centered, coded, electronic patient record
used in patient care enabled retrospective analysis of data collected prospectively. For survival
analysis, patients were censored when transplanted, transferred to hemodialysis at home or
elsewhere, peritoneal dialysis. Univariate Kaplan-Meier analysis was followed by multivariate
analysis with Cox's regression, using as variables age, race, gender, major co-morbid conditions,
epoetin-alfa and intravenous iron administered, and 15 laboratory tests.
Results: Median age was 59 years, epoetin-alfa (interquartile range) 18,162 (12,099, 27,741) units/
week, intravenous iron 301 (202, 455) mg/month, survival 789 (354, 1489) days. Median
hemoglobin was 116 (110, 120)g/L, transferrin saturation 29.7 (24.9, 35.1)%, serum ferritin 526
(247, 833) μg/L, serum albumin 39.0 (36.3, 41.5) g/L. Survival was better the higher the hemoglobin,
best with > 120 g/L. Epoetin-alfa effect on survival was weak but had statistically significant
interaction with intravenous iron. For intravenous iron, survival was best with 1–202 mg/month,
slightly worse with 202–455 mg/month; it was worst with no intravenous iron, only slightly better
with > 455 mg/month. Survival was worst with transferrin saturation ≤ 16%, serum ferritin ≤ 100
μg/L, best with transferrin saturation > 25%, serum ferritin > 600 μg/L The effects of each of
hemoglobin, intravenous iron, transferrin saturation, and serum ferritin on survival were
independently significant and not mediated by other predictors in the model.
Conclusion: Long term survival of maintenance hemodialysis patients was favorably affected by a
relatively high hemoglobin level, by moderate intravenous iron administration, and by indicators of
iron sufficiency. It was unfavorably influenced by a low hemoglobin level, and by indicators of iron
deficiency.
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Background
Deficiencies of erythropoietin and iron play a role in gen-
esis of the anemia of Chronic Kidney Disease (CKD) and
End Stage Renal Disease (ESRD) patients treated by
hemodialysis (HD). Both are correctible. Although treat-
ment with epoetin-alfa (EPO) and newer erythrocyte
stimulating agents (ESA) has mitigated its severity, some
recent studies have reported adverse outcomes of effective
anemia correction with EPO and other ESAs [1-3].
Iron deficiency anemia is prevalent in 2–8% of adult
women [4], latent iron deficiency (i.e., without anemia)
may be twice as frequent [5]. In a complex, stratified ran-
dom US population sample of 15,387 subjects, anemia
(hemoglobin < 110 g/L in women, < 120 g/L in men) was
found in 569 (3.9%), in 179 of whom creatinine clear-
ance was < 50 ml/min. Of these, < 33% were iron suffi-
cient (TSAT ≥ 20%, serum ferritin ≥ 100 μg/L) [6]. Thus
iron deficiency and iron deficiency anemia are highly
prevalent in renal insufficiency even before dialysis is
required. Recent studies have confirmed this [2,7-11], and
intravenous (IV) iron replenishment slowed deterioration
of renal function in CKD [7,8].
Possible adverse effects of raising hemoglobin (Hb) con-
centration to > 120 g/L on patient survival have attracted
wide attention recently, and have resulted in warnings
about the practice. The importance of adequate iron avail-
ability was stressed in the earliest EPO studies in HD
patients [12], yet few reports on the effects of EPO and
newer ESAs have explicitly addressed the need of patients
for adequate iron [2,3,10], and ESA effects have been
tested in CKD patients at least 25–30% of whom had evi-
dence of iron deficiency at study start before the ESA was
given [2,3,10]. Also, widely publicized guidelines suggest-
ing adverse effects of serum ferritin levels > 500–1,000 μg/
L [13-16] have cautioned about IV iron usage.
We recently reported the effect of a particular patient-cen-
tered electronic patient record (EPR) on mortality in
1,790 patients treated by in-center HD in 3 dialysis units
over 7–9 years [17]. That analysis was limited in at least
two respects. First, patient mortality was the measured
outcome; second, the effect of various prognostic factors
on mortality was assessed one predictor at a time. Here,
we apply univariate and multivariate methods to examine
the effects of various factors, including EPO and IV iron
administration, on patient survival. The data analyzed
were those collected prospectively during patient care,
using the EPR, from 1998 onward. We report on long-
term survival of these patients in relation to anemia and
its management with EPO and IV iron.
Methods
Patients
A total of 1790 patients was available who were treated by
maintenance in-center HD in 3 dialysis units managed by
The Rogosin Institute (New York, NY), affiliated with New
York Presbyterian Hospital and Weill Medical College of
Cornell University; 1774 were included in the present
study. Because they had hemolytic anemias and persist-
ently high serum ferritin levels in association with the pri-
mary disease, 15 patients with sickle cell anemia and
sickle cell trait were excluded, as well as one with acute
myeloid leukemia who had recently received a bone mar-
row transplant and total body irradiation. The patient
characteristics were described in detail previously [17]. All
started the in-center HD course between January 1, 1998
and December 31, 2006. The present study includes sur-
vival follow up until June 30, 2007.
EPO, IV iron, and other medications were prescribed by
attending nephrologists using an approach guided, with
assistance of an anemia management team, by then cur-
rent NKF DOQI guidelines available in 2002 [14] and
2006 [15]. EPO was administered IV. Three IV iron prep-
arations were used: iron dextran (InFed®), iron sucrose
(Venofer®), and sodium ferric gluconate (Ferrlecit®). Clin-
ical practice was also influenced by changing mandates
from the Center for Medicare and Medicaid Services
(CMS) and by publications suggesting adverse effects of
high serum ferritin levels [13].
A comprehensive patient-centric, computerized record
system (Disease Manager Plus™, MIQS, Inc., Boulder CO),
in which data are stored in coded, extractable, form was
used in patient care. Described in detail elsewhere, it ena-
bled patient management and the present analyses [17].
Variables abstracted for analysis included:
￿ Demographic: age at treatment start, race; gender; pri-
mary renal disease leading to ESRD
￿ Co-morbid diseases present at or before treatment start:
arteriosclerotic heart disease (ICD9-CM 410–414, 36.06,
36.07, 36.1), cerebrovascular disease (ICD 430–438),
peripheral vascular disease (ICD 440, 441, 443, 785.4,
V49.7, 84.1), malignancy (ICD 149–208), diabetes melli-
tus Types I (ICD 250.x1) and II (ICD 250.x0), AIDS (ICD
042), peptic ulcer disease (ICD 531–533).
￿ Drugs: EPO and IV iron recorded as administered during
HD treatments on 430,077 and 135,595 occasions respec-
tively. During the course of the study there were three
double blind dose equivalence studies, comparing then
new ESAs with EPO. In all, these involved 3,531 (0.82%)BMC Nephrology 2009, 10:6 http://www.biomedcentral.com/1471-2369/10/6
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of all ESA administrations. Data from these double blind
studies have been included using the appropriate dose of
EPO and its assumed equivalent.
￿ Laboratory test results: Hb, red blood cells (RBC), mean
corpuscular volume (MCV), mean corpuscular hemo-
globin (MCH), mean corpuscular hemoglobin concentra-
tion (MCHC), serum iron, transferrin saturation (TSAT),
total iron binding capacity (TIBC), serum calcium, serum
phosphorus, calcium × phosphorus product, serum intact
parathyroid hormone (iPTH), Kt/V, and serum albumin
were obtained on admission and monthly thereafter.
Serum ferritin was measured 3-monthly. Approximately
58,980 measurements of each set of laboratory tests were
analyzed.
Patients who continued in-center HD without interrup-
tion were followed until death or study termination on
June 30, 2007. Save for the 29 who returned to in-center
HD within 3 months of the last in-center HD treatment,
those treated subsequently in another dialysis unit, or by
kidney transplantation, home HD, or peritoneal dialysis
were censored at the time of their last in-center HD treat-
ments.
Statistical Analysis
Survival was defined from the date of the first in-center
HD during the study period to death or termination of the
follow-up (June 30, 2007), at which time patients still
alive were treated as censored for survival analyses.
Patients were also censored at the last in-center HD treat-
ment before kidney transplantation, start of home HD,
peritoneal dialysis, or transfer to another dialysis unit for
in-center maintenance HD treatment.
Since each patient had numerous administered doses of
EPO and IV iron, we obtained each patient's EPO dose as
units per week, and IV iron dose as mg per month. This
single characterization for each patient allowed us to sum-
marize rates of administration of EPO and IV iron for each
patient, and thereby assess the effects of these treatments
on survival. Similarly, each hematological parameter for
each patient was summarized by the mean value within
that patient, thereby representing an average assessment
over the duration of observation for that patient. The
effects of various predictors on survival discussed herein
should therefore be interpreted as "between-patient"
rather than "within-patient" effects.
While EPO and IV iron dosages and hematological predic-
tors are measured on interval scales, we examine these
predictors both as continuous and as categorical variables
for ease of interpretation. For Hb, serum iron, TSAT,
serum ferritin, and other laboratory variables clinically
relevant specific categorizations and cut-offs are used.
We employed standard regression techniques for survival
data. Kaplan-Meier curves were obtained [18] for univari-
ate analyses and, to ensure adequate consideration of con-
founding factors, Cox multivariate regression analysis
[19]. The following co-variates were considered in the
model building stage of analysis: age at treatment start,
race, gender, primary renal disease leading to ESRD, pres-
ence or absence of one or more co-morbid conditions,
EPO and IV iron dose administered, and hemoglobin,
RBC, MCV, MCH, MCHC, serum iron, TSAT, TIBC, serum
calcium, serum phosphorus, calcium × phosphorus prod-
uct, iPTH, Kt/V, and serum albumin. We used a backward
regression approach in multivariate set up to eliminate
non-significant (p > 0.05) predictors from the model. We
analyzed the EPO interaction effects on patient survival
with IV iron, TSAT and serum ferritin in three models each
of which contained EPO administered and one only of IV
iron administered, TSAT, or serum ferritin along with all
other significant predictors of survival. Thus, the above
mentioned three interactions were assessed but only as
two-factor interactions, and one interaction at a time with
categorical characterization of the interacting variables.
Only when the test for interactions was significant (P <
0.05), we looked at the pair-wise hazard ratios for assess-
ing effects of interacting variables.
EPO was administered to 1731 patients (97.6%), TSAT
values were available on 1690 patients (95.3%), and
serum ferritin values on 1710 (96.4%). Certain variables
which were skewed in nature were log transformed.
Study Approval
The study was approved by the Institutional Review Board
of Weill Medical College of Cornell University.
Results
Patients
The patient characteristics are summarized in Table 1.
Mean age at study start was 59 years, 53% were male, 43%
White, and 36% Black; 18% were Hispanic. The primary
disease leading to renal failure was glomerulonephritis in
15%, hypertension in 24%, and diabetes mellitus Types I
and II in 4% and 32% respectively. Co-morbid conditions
were: arteriosclerotic heart disease in 23%. cerebral vascu-
lar disease in 8%, peripheral vascular disease in 12%,
malignant disease in 9%, AIDS in 4.2%, diabetes mellitus
Types I and II in 4.6 and 38% respectively, and peptic
ulcer in 2.1%; 649 patients (36.6%) had none of these co-
morbid conditions.
Survival duration and EPO and IV iron administered are
summarized in Table 2. Median survival was 789 days
(interquartile range 354 and 1489). The median EPO and
IV iron administered were, respectively, 18.16 (IQR 12.10BMC Nephrology 2009, 10:6 http://www.biomedcentral.com/1471-2369/10/6
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and 27.74) 103 units/week and 301.2 (IQR 201.6 and
454.7) mg/month.
Laboratory test results were analyzed for each patient for
the duration that the patient was in the study, i.e., until
censoring or death. Median, mean, and standard devia-
tions are displayed in Table 3. Median Hb was 116.1 g/L,
MCH 30.7 pg, MCHC 322.8 g/L, serum iron 17.34 μmol/
L, TSAT 29.76%, and serum ferritin 526.2 μg/L. Median
Kt/V was 1.63, and median serum albumin 39.1 g/L.
Table 1: Selected patient data at time of the first in-center HD treatment
%
Patients 1774
Age at start of first in-center HD treatment 59 ± 16.2
Gender (male/female) 944:830 53.2:46.8
Race (White: Black: Other/Unknown) 42.7:36.3:21.0
Primary disease leading to renal failure
Glomerulonephritis 259 14.6
Hypertension 427 24.1
Diabetes mellitus Type I (juvenile) 71 4
Diabetes mellitus Type II (adult onset or unspecified) 577 32.4
Other 440 24.8
Major known co-morbid conditions at study entry
Arteriosclerotic heart disease 410 23.1
Cerebral vascular disease 148 8.3
Peripheral vascular disease 215 12.1
Malignant disease 161 9.1
AIDS 74 4.2
Diabetes mellitus Type I (juvenile) 82 4.62
Diabetes mellitus Type II (adult onset or unspecified) 670 37.8
Peptic ulcer disease 37 2.1
Previous kidney transplant 74 4.2
Table 2: Median patient survival, and median EPO and IV iron given for the total study duration
Median Interquartile range (25%) Interquartile range (75%)
Survival duration (days) 789 354 1489
EPO administered per week (103 units) 18.16 12.1 27.74
IV iron administered per month (mg) 301.2 201.6 454.7BMC Nephrology 2009, 10:6 http://www.biomedcentral.com/1471-2369/10/6
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Median serum calcium was 2.35 mmol/l, serum phospho-
rus 1.76 mmol/L, calcium × phosphorus product 4.11
mmol2/L2, and intact PTH 301.4 ng/L.
Univariate Analysis
Survival curves were calculated for the patient group as a
whole (Figure 1), for mean EPO per week and for mean IV
iron per month of patient follow up. Patients were catego-
rized into three groups (low, medium, high) based on the
dose of each drug administered. In the case of IV Iron,
patients who did not receive IV iron (No-IV) were also
included along with the three other groups. Cut-offs for
the various groups were based purely on the results of the
statistical analysis (Table 2). For EPO, survival was rela-
tively worse in the high dose group (> 27.74 103 units per
week), and relatively best in the low dose group (≤ 12.10
103 units per week) (Figure 2). For IV iron, survival was
worst in those who received no IV iron at all (Figure 3),
and was almost as bad in the high dose group (≥ 455 mg/
month). It was relatively best in patients receiving a rela-
tively low dose (1–202 mg per month), slightly worse in
those receiving a relatively higher dose (202.1–455 mg
per month).
All hematological parameters measured were quantitative
but, to facilitate clinical interpretation, survival curves
were obtained for selected clinically relevant categoriza-
tions of these parameter values. For Hb, survival was rela-
tively the worst in those with an overall mean ≤ 100 g/L,
and was progressively better with mean Hb levels of
100.1–110, 110.1–120, best in those with mean values >
120 g/L (Figure 4). For serum iron, survival was worst with
a median serum iron level ≤ 5.4 μmol/L, best with a level
10.7–19.7 μmol/L (Figure 5). For TSAT, survival was worst
with a mean TSAT ≤ 16%, and progressively better with
mean TSAT levels 16.1–20, 20.1–25, and > 25% (Figure
6). No explicit relationship was observed between TSAT
Table 3: Patient median and mean values of tests analyzed 
during the total study duration
Laboratory test Median Mean SD
Tests relevant to anemia
Hemoglobin (g/L) 116.1 114.1 10.3
Hematocrit (Proportion of 1.0) 36.2 35.7 3.09
RBC (10^12/L) 3.76 3.76 0.4
MCV (fl) 94.6 94.6 7.14
MCH (pg) 30.7 30.5 2.54
MCHC (g/L) 322.8 322.3 12.7
Serum iron (μmol/L) 17.34 15.29 5.5
TSAT (%) 29.76 30.6 9.39
Total iron binding capacity (μmol/L) 42.46 44.05 10.41
Serum ferritin (μg/L) 526.2 593.9 426.76
Tests relevant to dialysis adequacy and nutrition
Kt/V 1.63 1.61 0.27
Serum albumin (g/L) 39.1 38.7 4.2
Tests relevant to calcium and phosphorus metabolism
Serum calcium (mmol/L) 2.35 2.34 0.17
Serum phosphorus (mmol/L) 1.76 1.81 0.57
Serum calcium × phosphorus (mmol2/L2) 4.11 4.2 1.07
Intact parathyroid hormone (ng/L) 301.4 385.1 330.21
Estimated proportion of patients surviving Figure 1
Estimated proportion of patients surviving.
Estimated proportion of patients surviving by levels of EPO  administration Figure 2
Estimated proportion of patients surviving by levels 
of EPO administration. Although the differences were 
small, survival was best in those receiving a low dose of EPO 
(L = ≤ 12.1 103 units per week), slightly worse with a medium 
dose (M = 12.1–27.7 103 units per week), and worst in those 
receiving a high dose (H = > 27.7 103 units per week).BMC Nephrology 2009, 10:6 http://www.biomedcentral.com/1471-2369/10/6
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level and IV iron administered. For example, 17% of
patients with TSAT levels ≤ 20% had received no IV iron,
but 50% had received > 455 mg/month (Table 4). For
serum ferritin survival was worst with mean serum ferritin
≤ 100 μg/L, slightly better with levels between 100 and
300 μg/L (Figure 7). No explicit relationship was observed
between serum ferritin level and IV iron administered. For
example, 40% of patients with serum ferritin levels > 600
μg/L had received IV iron > 455 mg/month but 18% had
received no IV iron (Table 5). The best survival was in the
three groups with mean serum ferritin levels between 300
and 600, 600 and 1000, and > 1000 μg/L, which differed
little from each other. For Kt/V survival was worst with
mean Kt/V ≤ 1.2, successively better with Kt/V 1.21–1.4,
1.41–1.6, and best with Kt/V > 1.6. For serum albumin,
Estimated proportion of patients surviving by levels of IV iron  administration Figure 3
Estimated proportion of patients surviving by levels 
of IV iron administration. Survival was best in those 
receiving a low dose of IV iron (L = 1–202 mg per month), 
and slightly worse in those receiving a moderate dose (M = 
202–455 mg per month). Survival was much worse in those 
who received a high dose (H = > 455 mg per month) and in 
those who did not receive IV iron (∅ = NO IV).
Estimated proportion of patients surviving by four levels of  hemoglobin Figure 4
Estimated proportion of patients surviving by four 
levels of hemoglobin.
Estimated proportion of patients surviving by four levels of  serum iron Figure 5
Estimated proportion of patients surviving by four 
levels of serum iron.
Estimated proportion of patients surviving by four levels of  TSAT Figure 6
Estimated proportion of patients surviving by four 
levels of TSAT. The number of patients who received vari-
ous levels of IV iron over the time at risk in each of the four 
TSAT levels is shown in Table 4.BMC Nephrology 2009, 10:6 http://www.biomedcentral.com/1471-2369/10/6
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median survival was worst with a mean value ≤ 35 g/L,
best with a mean value > 40 g/L.
Multivariate analysis
Survival duration was first analyzed using data for all years
1998–2006 for all patients in all 3 dialysis units. Included
in the model were age at treatment start, race, gender,
presence or absence of co-morbid conditions, EPO
administration in 3 ranks (0–12.1, 12.11–27.7, and >
27.7 103 units per week), IV iron administration in 4 ranks
(0, 1–202, 202–455, and > 405 mg per month), and
median values for all laboratory test results. Race, gender,
dialysis center, time of entry into the study, serum iron,
TIBC, MCV, MCH, serum calcium, and serum phosphorus
were eliminated from the model in backward elimination
as they failed to reach the level of significance (P < 0.05).
The results, summarized in part in Table 6, demonstrate
the powerful independent positive effect on survival of
intravenous iron administered in low (≤ 202 mg/month)
and medium (202–455 mg/month) doses. TSAT levels >
25% and serum ferritin levels > 300 μg/L were also inde-
pendently associated with a positive effect on survival.
Serum albumin > 40 g/L and Kt/V > 1.6, a measure of dial-
ysis adequacy, were associated with a positive effect on
survival, as has long been recognized [20]. TIBC, MCHC,
calcium × phosphorus product, and PTH were factors that
also independently affected survival.
Analysis of the EPO IV iron interaction effect on patient 
survival
This analysis was done with a model in which only IV iron
administered and EPO administered were included as
interactions along with all the other significant predictors
of survival. The results are summarized in Table 7. Esti-
mated survival curves are displayed in Figure 8. For IV
iron, survival was uniformly worst for those who received
no IV iron, best with 1–202 mg/month, and slightly worse
with 202–455 mg/month. For those who received IV iron
> 455 mg/month, survival was only slightly better than in
the no IV iron group. The effect of EPO on survival was
weak but had statistically significant interaction with IV
iron. In particular, EPO without IV iron did not seem to
have any beneficial impact on survival, whereas with IV
iron EPO did have some beneficial effect on survival,
albeit small.
Analysis of the TSAT EPO interaction effect on patient 
survival
This analysis was done with a model in which only TSAT
and EPO administered were included as interactions
along with other significant predictors of survival. As com-
pared with patients with a mean TSAT > 25%, the hazard
ratios for those with TSAT ≤ 16% was 6.62, for TSAT
16.01–20 it was 2.59, and for TSAT 20.01–25 it was 1.95.
As compared with patients who received EPO > 27.7 103
units/week the hazard ratios for those who received 0–
12.1 and 12.1–27.7 103 units/week were, respectively,
0.61 and 0.81. An interaction of TSAT and EPO adminis-
tration on survival was not significant. The estimated sur-
vival curves (Figure 9), demonstrate the powerful effect of
low TSAT levels on survival even after controlling for other
significant predictors of survival.
Estimated proportion of patients surviving by five levels of  serum ferritin Figure 7
Estimated proportion of patients surviving by five 
levels of serum ferritin. The number of patients who 
received various levels of IV iron over the time at risk in each 
of the five serum ferritin levels is shown in Table 5.
Table 4: The number of patients who received various levels of 
IV iron over the time at risk in each of the four TSAT levels
TSAT level IV iron level (mg/month)
0 1 – 202 202.1 – 455 > 455
≤ 16% 16 3 16 45
16.1 – 20% 14 6 30 41
20.1 – 25% 20 18 142 91
> 25% 126 219 695 263
Table 5: The number of patients who received various levels of 
IV iron over the time at risk in each of the five serum ferritin 
levels
Serum ferritin level IV iron level (mg/month)
0 1 – 202 202.1 – 455 > 455
≤ 100 μg/L 30 23 34 34
100.1 – 300 μg/L 37 75 162 124
300.1 – 600 μg/L 31 65 233 123
600.1 – 1000 μg/L 34 52 291 161
> 1000 μg/L 29 28 161 53BMC Nephrology 2009, 10:6 http://www.biomedcentral.com/1471-2369/10/6
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Analysis of the serum ferritin EPO interaction effect on 
patient survival
This analysis was done with a model in which only serum
ferritin and EPO administered were included as interac-
tion along with other significant predictors of survival.
The results are summarized in Table 8. There was a signif-
icant adverse effect on survival of a serum ferritin level ≤
100 μg/L at all three levels of EPO administration (0–
12.1, 12.11–27.7 103 units/week), i.e, interactions A, F,
and K; the hazard ratios were, respectively, 7.37, 5.93, and
3.39. The adverse effect on survival was still apparent but
less marked when serum ferritin levels between 100 and
300  μg/L were considered (interactions B, G, and L).
When higher serum ferritin levels were considered
(between 300 and 600, 600 and 1000 and > 1000 μg/L),
with a single exception (Interaction M) no statistically
adverse effects on survival were observed.
Discussion
Hemoglobin
In a recent study of almost 160,000 HD patients who had
Medicare as their primary payer both highly variable and
persistently and transiently low Hb levels (< 110 g/L) in
the first 6 months of 2004 were associated with increased
risk of death in the second six months of the same year,
whereas transiently and persistently high Hb levels (> 125
g/L or > 120 g/L) were not [21].
Taking confounding factors and other significant predic-
tors of survival into account, our long-term observations
showed clearly that patient survival was better the higher
the Hb, and that survival was best with a Hb level > 120 g/
L. The 50% survival estimates for Hb > 120, 110–120,
100–110, and ≤ 100 g/L were, respectively, 1198, 1144,
751, and 534 days.
Recent controlled clinical trials that reported adverse
effects of a high Hb level in CKD patients [2,3] are the
basis for warnings about adverse effects of raising Hb
above 120 g/L. The trials were of short duration, without
reference to the iron status of the patients or the known
iron deficiency of CKD patients [6-9], and were designed
to increase the Hb concentration by manipulating the ESA
dose. Moreover, supplementary iron was not provided to
patients whose relatively dormant bone marrow would
have been stimulated by the ESA, thereby depleting iron
stores available for metabolic functions other than Hb
production [2,3,9,10].
The development of thrombocytosis is one possible
mechanism for adverse effects of ESAs in the presence of
depleted iron stores. An inverse relationship between
TSAT and platelet counts and platelet volume has been
demonstrated in women with iron deficiency anemia
[22]. Evidence has recently been presented suggesting
Table 6: Cox Regression: results of a model in which all data for all units are included.
Factors analyzed Reference Value* Hazard Ratio (HR) HR 95% Confidence Limits
Age at treatment start (per year) 1.045 1.04, 1.05
Co-morbid conditions (None) ≥ 1 0.72 0.60, 0.87
EPO 0–12.1 103 units/week > 27.7 103 units/week 1.5 1.14, 1.96
EPO 12.1 – 27.7 103 units/week > 27.7 103 units/week 1.35 1.10, 1.67
IV iron 0 mg/month > 455 mg/month 1.27 0.91, 1.77
IV iron 1 – 202 mg/month > 455 mg/month 0.27 0.20, 0.36
IV iron 202 – 455 mg/month > 455 mg/month 0.49 0.69, 0.61
Hb ≤ 100 g/L > 120 g/L 2.83 1.92, 4.16
Hb 100.1 – 110 g/L > 120 g/L 2.69 1.98, 3.67
Hb 110.1 – 120 g/L > 120 g/L 1.67 1.31, 2.14
TSAT ≤ 16% > 25% 1.4 0.92, 2.10
TSAT 16.01 – 20% > 25% 1.33 0.94, 1.88
TSAT 20.01 - 20% > 25% 1.41 1.14, 1.76
Serum ferritin ≤ 100 μg/L > 1000 μg/L 3.64 2.49, 5.32
Serum ferritin 101–300 μg/L > 1000 μg/L 2.2 1.66, 2.90
Serum ferritin 301–600 μg/L > 1000 μg/L 1.45 1.11, 1.89
Serum ferritin 601–1000 μg/L > 1000 μg/L 1.14 0.88, 1.49
Serum albumin ≤ 35 g/L > 40 g/L 3.41 2.58, 4.50
Serum albumin 35.1–40 g/L > 40 g/L 1.28 1.05, 1.57
Kt/V ≤ 1.2 > 1.6 2.18 1.56, 3.05
Kt/V 1.21-1.4 > 1.6 1.37 1.03, 1.73
Kt/V 1.41-1.6 > 1.6 0.87 0.70, 1.07
* The numbers of patients in the reference groups are below, in parenthesis: EPO > 27.7 103 units/week (n = 400); IV iron > 455 mg/month (n = 
442); Hb > 120 g/L (n = 442); TSAT > 25% (n = 1303); serum ferritin > 1000 μg/L (n = 266); serum albumin > 40 g/L (n = 688); Kt/V > 1.6 (n = 950)BMC Nephrology 2009, 10:6 http://www.biomedcentral.com/1471-2369/10/6
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that, in HD patients given high doses of EPO to achieve
Hb ^ 130 g/L, iron depletion and the associated relative
thrombocytosis might play a role in the reported
increased mortality [23].
Studies on cytokines in chronic HD patients point to
another possible mechanism for adverse effects on mor-
bidity and mortality of EPO administration in iron defi-
cient or marginally iron sufficient patients. The pro-
inflammatory cytokine TNF-α was reported to be about 6
times higher in HD patient plasma than in controls (5.6 ±
0.9 versus 0.9 ± 0.1 pg/ml) [24]. In another study, plasma
concentrations of TNF-α, the anti-inflammatory cytokine
IL-4, and total peroxide concentrations were measured in
a 90-day randomized controlled trial in patients receiving
EPO without or in combination with IV iron [25]. Patients
receiving both IV iron and EPO had lower pro-inflamma-
tory cytokine TNFa and higher anti-inflammatory
cytokine IL-4 levels, as well as lower levels of total perox-
ide a marker of free radical concentration.
These observations suggest a possible role for these
cytokines in relation to the adverse effect of iron defi-
ciency on morbidity and mortality in EPO treated CKD
and HD patients in whom there was inattention to the
iron status.
Non-hematological effects of iron deficiency
The renal literature refers rarely to non-hematological
consequences of iron deficiency. Iron is a key component
of many cellular enzymes, including oxidases, catalases,
peroxidases, aconitases, and nitric oxide synthetases [26-
28]. Iron deficiency adversely affects metabolic processes
that include electron transport, catecholamine metabo-
lism, DNA synthesis, and several enzyme systems [4]. Iron
is an integral part of the requirement of mitochondrial
enzymes of the electron transport chain, and of cyto-
chromes and iron-sulfur proteins required for oxidative
phosphorylation of ADP to ATP, and iron deficiency in
rats leads to oxidant-induced mitochondrial damage [29].
Iron deficiency results in decreased exercise performance
in rats, corrected rapidly by iron but not by blood transfu-
sion [30,31]. In HD patients iron deficiency without evi-
dence of iron deficiency anemia has been reported, and IV
iron repletion was associated with positive effects on
Estimated proportion of patients surviving by combinations  of levels of IV iron and of EPO administration Figure 8
Estimated proportion of patients surviving by combi-
nations of levels of IV iron and of EPO administra-
tion. Low (L), medium (M) and high (H) levels of iron and 
EPO administered are indicated in the boxes by the appro-
priate symbol, and those who received no iron by the symbol 
∅. The worst survival estimates were in patients who 
received no iron (Fe ∅). Survival estimates were slightly, but 
little better in those in the high iron group (Fe H). the best 
survival estimates were in the low iron group (Fe L), and they 
were slightly worse in the medium iron group (Fe M). For 
each of the four levels of IV iron administered, survival was 
best in the low EPO Group (EPO L), and worst in the high 
EPO group (EPO H), but the differences were very small.
Table 7: IV iron EPO administered interaction: hazard ratios and patient survival
Interaction Patients (n) IV Iron (mg/month) EPO (103 u/week) Hazard HR 95% Confidence Limits Median Survival (days)
A 21 0 0–12.1 0.82 0.37, 1.83 317
B 89 1–202 0–12.1 0.45 0.28, 0.73 1623
C 238 202.1–455 0–12.1 0.86 0.60, 1.23 1104
D 83 >455 0–12.1 1.37 0.81, 2.32 314
E 80 0 12.1–27.7 3.12 2.02, 4.81 152.5
F 124 1–202 12.1–27.7 0.35 0.23, 0.52 1672
G 458 202.1–455 12.1–27.7 0.68 0.51, 0.92 993
H 200 > 455 12.1–27.7 1.6 1.11, 2.31 331.5
I 53 0 > 27.7 1.27 0.72, 2.24 282
J 32 1–202 > 27.7 0.41 0.24, 0.71 1247.5
K 187 202.1–455 > 27.7 0.52 0.38, 0.72 985
L 158 > 455 > 27.7 620.5BMC Nephrology 2009, 10:6 http://www.biomedcentral.com/1471-2369/10/6
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serum albumin, muscle mass, hospitalization, and blood
pressure [32]. Low serum iron (< 8.1 μmol/L) and low
TSAT levels were shown to be associated with increased
mortality [33]. In the present study survival was worst
with very low levels of serum iron (≤ 5.4 μmol/L), TSAT (≤
20%), and serum ferritin (≤ 100 μg/L), and in those who
received no IV iron.
When ESAs are administered to patients deficient or mar-
ginally sufficient in iron, the demands for iron for Hb pro-
duction are likely to further deplete iron available for
other essential metabolic processes The rise in plasma
TNF-α and decrease in IL-4 levels may also be important
as noted above. We conclude that close attention to iron
repletion and iron sufficiency is essential for HD patient
well-being.
Seeking an optimal dose of IV iron for hemodialysis 
patients
Widely publicized clinical guidelines caution about
administering IV iron to HD patients with serum ferritin
levels above thresholds varying from 500 to 800 μg/L [14-
16,34], but recent reviews have concluded that an evi-
dence based guideline for an upper limit of serum ferritin
is not available [35,36]. Ferritin levels up to 1200 μg/L
were not associated, in a large study, with an increase in
all cause mortality [37]. The present study confirms this
by demonstrating clearly that serum ferritin levels of
between 600 and 1,000 and > 1,000 μg/L were not associ-
ated with adverse effects on survival in univariate and
multivariate analysis. There is no clear evidence for the
association of infection with high serum ferritin levels in
dialysis patients [38-40]. We found that whereas malnu-
trition and infections are, not surprisingly, associated with
patient deaths, neither a serum ferritin level > 600 μg/L
nor a high dose of iron (> 455 mg/month) was signifi-
cantly associated with either infection or malnutrition
(Table 9). That the best survival was observed in patients
with a serum iron level > 10.7 μmol/L and with a TSAT
level > 25% also confirms the report of Kalantar-Zadeh
and colleagues [37].
Survival decreases sharply as serum iron and TSAT levels
decrease in both univariate and multivariate analyses: this
strongly suggests that serum iron > 10.7 μmol/L and TSAT
> 25% are reasonable targets to assess iron sufficiency in
HD patients. When the needed amount of IV iron is con-
sidered in relation to these targets and survival our data
showed that amounts up to 455 mg per month were asso-
ciated with improved survival. On the other hand,
amounts > 455 mg per month, close to the reported cut-
off point of 400 mg per month reported by Kalantar-
Zadeh and colleagues [37], were associated with worsened
survival.
In this study we summarized hematological parameters
and rates of administration of EPO and IV iron for each
patient to assess the effects of these parameters and treat-
ments on survival. Assessing effects of temporal changes
in treatments or hematological parameters on patient's
survival is also important and is subject of future investi-
gation.
Conclusion
￿ In HD patients a high Hb level (> 120 g/L) was associ-
ated with the best survival, a relatively low Hb level (≤ 110
g/L) with the worst.
￿ With respect to parameters reflecting iron status, the best
survival was associated with a high serum iron (> 10.7
μmol/L), TSAT (> 25%), and serum ferritin (> 600 μg/L),
the worst with low levels for all three measurements.
Estimated proportion of patients surviving by combinations  of four levels of TSAT and three of EPO administration Figure 9
Estimated proportion of patients surviving by combi-
nations of four levels of TSAT and three of EPO 
administration. TSAT levels are shown in the boxes and 
low (L), medium (M) and high (H) levels of EPO administered 
are indicated by the appropriate symbol. The 3 worst survival 
estimates were in patients with TSAT ≤ 16%; of the three, 
the best estimate was for the low EPO (L) group. The three 
best survival estimates were in patients with TSAT > 25%; of 
the three, the best was for the low EPO (L) group. Estimates 
for intermediate levels of each variable are shown but not 
identified specifically. Survival in patients with TSAT 16.01–
20% was better than that of those with TSAT ≤ 16%; in those 
with TSAT 20.01–25% it was better than in those with TSAT 
16.01–20%, and worse than in those with TSAT > 25%. For 
each of these two TSAT levels, as well as for the two other 
TSAT levels, survival was best in the low EPO (L) group, and 
worst in those in the high (H) EPO group.BMC Nephrology 2009, 10:6 http://www.biomedcentral.com/1471-2369/10/6
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￿ The influence of IV iron on survival was profound. The
best survival was in patients receiving 1–202 mg per
month, the worst in patients receiving no IV iron at all,
and in those receiving > 455 mg per month.
￿ The influence of EPO on survival was very small, but the
best survival was in patients receiving EPO ≤ 12.1 103
units per week.
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